Praxis Precision Medicines, Inc.
PRAXNasdaq
$314.41
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↑ +486.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.1B
Enterprise Value
$8.3B
P/E
—
P/S
—
P/B
6.4
EV/EBITDA
—
PEG
—
FCF Yield
-3.1%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$326.3M
Free Cash Flow (TTM)
-$282.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-23.1%
ROIC
-45.3%
Debt / Equity
—
Net Cash
$786.9M
Return 1Y
+472.3%
Company profile
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression.
- CEO
- Marcio Souza
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- Massachusetts
- Website
- praxismedicines.com
Management & directors
- Souza MarcioChief Executive Officer
- Kelly Timothy EdwinChief Financial Officer
- Mastrocola LaurenPrincipal Accounting Officer
- Nemiroff AlexGeneral Counsel and Secretary
- Sniecinski MeganChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
PRAX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$3.20↓ -2.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $2.4M | $8.6M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$62.0M | -$167.3M | -$215.0M | -$126.4M | -$200.2M | -$326.2M |
| Net income | -$61.8M | -$167.0M | -$214.0M | -$123.0M | -$183.0M | -$303.0M |
| Diluted EPS | -$7.86 | -$3.94 | -$69.65 | -$18.69 | -$10.21 | -$13.48 |
| Operating cash flow | -$52.6M | -$124.6M | -$185.0M | -$111.1M | -$131.8M | -$249.1M |
| Free cash flow | -$52.6M | -$125.6M | -$185.5M | -$111.2M | -$131.8M | -$249.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -5164.4% | -2340.3% | — |
| Net margin | — | — | — | -5026.6% | -2139.6% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $357,000.00 | $302,000.00 | $7.5M | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$37.5M | -$56.8M | -$64.0M | -$74.7M | -$76.1M | -$78.4M | -$97.0M | -$105.9M |
| Net income | -$32.7M | -$51.9M | -$58.7M | -$69.3M | -$71.1M | -$73.9M | -$88.6M | -$92.6M |
| Diluted EPS | -$1.74 | -$2.75 | -$2.88 | -$3.29 | -$3.31 | -$3.36 | -$3.52 | -$3.20 |
| Operating cash flow | -$27.3M | -$27.5M | -$56.1M | -$53.0M | -$54.7M | -$65.1M | -$76.3M | -$86.2M |
| Free cash flow | — | -$27.5M | — | -$53.0M | -$54.7M | -$65.1M | -$76.3M | -$86.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -10500.8% | -18819.5% | -857.0% | — | — | — | — | — |
| Net margin | -9153.2% | -17188.7% | -786.3% | — | — | — | — | — |
Company news
Jun 22, 2026
- 28d agoPraxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designationinvestorshub.advfn.com
- 28d agoPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variantsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Souza Marcio· Chief Executive Officer | Gift | 2,600 | $0.00 | $0.00 | filing |
| 2026-07-08 | Souza Marcio· Chief Executive Officer | Gift | 20,521 | $0.00 | $0.00 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 2,854 | $311.91 | $890,202.56 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 1,750 | $310.89 | $544,055.75 | filing |
| 2026-06-24 | DeSimone Jill | Option exercise | 3,034 | $147.30 | $446,908.20 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 1,279 | $314.90 | $402,758.38 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 1,240 | $308.24 | $382,221.32 | filing |
| 2026-06-24 | DeSimone Jill | Option exercise | 8,566 | $44.25 | $379,045.50 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 1,004 | $312.83 | $314,081.32 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 999 | $309.38 | $309,073.62 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 837 | $315.71 | $264,245.09 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 683 | $306.77 | $209,521.86 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 504 | $313.66 | $158,086.15 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 320 | $305.31 | $97,699.20 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 120 | $303.13 | $36,375.24 | filing |
| 2026-06-24 | DeSimone Jill | Sale | 10 | $301.44 | $3,014.40 | filing |
| 2026-06-10 | Chodakewitz Jeffrey | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-06-10 | Arbuckle Stuart A | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-06-10 | YOUNG WILLIAM D | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-06-10 | DeSimone Jill | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-06-10 | Cudkowicz Merit Ester | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-06-10 | MITCHELL DEAN J | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-06-10 | KINDLER JEFFREY B | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-06-10 | Norden Gregory | Award | 1,371 | $0.00 | $0.00 | filing |
| 2026-05-14 | Mastrocola Lauren· Principal Accounting Officer | Award | 127 | $167.94 | $21,328.76 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.